Warner Chilcott
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Warner Chilcott sits in the top decile of US sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count).
Warner Chilcott: 53 sponsored US clinical trials, none currently recruiting.
Warner Chilcott sponsors 53 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 47 completed. 29 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Postmenopausal Osteoporosis, with 4 trials.
Top-decile sponsor footprint
Warner Chilcott ranks in the top decile of sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
47 of 53 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
53 total, page 1 of 2
A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy
NCT02670785
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
NCT01939184
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
NCT01845649
Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction
NCT01810575
Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women
NCT01816139
Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)
NCT01455597
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
NCT01400776
Effect of Udenafil on Spermatogenesis
NCT01230541
Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin
NCT01113931
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
NCT01065012
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
NCT01004185
Treatment of Erectile Dysfunction II
NCT01037218
Treatment of Erectile Dysfunction I
NCT01037244
Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure
NCT00957034
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
NCT00918749
Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food
NCT00868907
A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
NCT00846196
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
NCT00713310
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
NCT00712322
Food Effects on the Relative Bioavailability of Different Dosages of Risedronate
NCT00717145
Bone Microarchitecture in Osteopenic Postmenopausal Women
NCT00577395
Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
NCT00635609
Treatment of Moderate to Severe Facial Acne Vulgaris
NCT00612573
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
NCT00699777
Asacol Acute Diverticulitis(DIVA)Study
NCT00554099
Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
NCT00755872
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00541658
Fecal Biomarker Study for Patients With Ulcerative Colitis
NCT00780507
A Comparison of Once a Day Dose Compared to 2 Doses/Day
NCT00505778
Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch
NCT00791856
Study of Safety and Efficacy of an Oral Contraceptive
NCT00477633
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
NCT00467259
Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers
NCT00751699
Study of Safety and Efficacy of an Oral Contraceptive
NCT00391807
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
NCT00577720
Study of Bleeding With Extended Administration of an Oral Contraceptive
NCT00338052
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
NCT00350415
A Study of Monthly Risedronate for Osteoporosis
NCT00247273
A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.
NCT00254618
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
NCT00106028
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
NCT00577837
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
NCT00778154
Study of Safety and Efficacy of an Oral Contraceptive
NCT00932321
Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
NCT00837746
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
NCT01070979
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
NCT00577850
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00349791
Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
NCT00619957
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
NCT00331214
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00338312
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 11 |
| Phase 3 | 27 |
| Phase 4 | 2 |
How the Warner Chilcott archive is shaped
53 indexed studies, none listed as recruiting (0% open); 47 completed (89%).
Phase mix: 29 late (III/IV) vs 21 early (I/II) (balanced across stages).
Top condition: Postmenopausal Osteoporosis (4 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Warner Chilcott: archived-pipeline peers nationwide
Peers matched on 53 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Warner Chilcott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 53 archived trials
- BioNTech SE · 53 trials · 36% recruiting
- Société des Produits Nestlé (SPN) · 53 trials · 2% recruiting
- W.L.Gore & Associates · 53 trials · 21% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Warner Chilcott page
53 registered trials is a research-attention snapshot, not an endorsement of Warner Chilcott or any single study.
- None of Warner Chilcott's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Postmenopausal Osteoporosis is the condition Warner Chilcott studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postmenopausal Osteoporosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Warner Chilcott pipeline card: 53 registered trials from official public datasets.Report a data error.